– USA, PA – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Dr. Sandra Swain (M.D.) to its Board of Directors. Dr. Swain has over 30 years of oncology clinical research experience and has served on both public company and non-profit boards.
“Immunome is pleased to welcome Sandra to the Board of Directors, especially given her extensive experience as a successful clinical researcher. Her deep understanding of oncology and patient care will add a valuable perspective as we advance AL102 through Phase 3 and prepare Investigational New Drug filings for IM-1021 and IM-3050,” said CEO, Dr. Clay Siegall.
About Dr. Sandra M. Swain
Dr. Sandra Swain has served as Associate Dean for Research Development at Georgetown University Medical Center since 2016, and as Professor of Medicine at Georgetown University Medical Center since 2007. She has also served as VP of Genetic Medicine at MedStar Health, a not-for-profit healthcare system, since 2018. Dr. Swain served on the board of directors of the American Society of Clinical Oncology from 2008-2013 and was ASCO President from 2012-13. Since 2007, Dr. Swain has served on the board of directors for Conquer Cancer, the ASCO Foundation, including as treasurer of the Executive Committee from 2016 to 2019 and on the Joint Investment Committee from 2016 to 2018. Dr. Swain previously served on the board of directors of Seagen Inc. from November 2022 until its acquisition by Pfizer Inc. in December 2023.
“I am drawn to Immunome’s commitment to developing transformative therapies that meaningfully improve patients’ lives,” said Dr. Sandra Swain. “Immunome’s promising pipeline, talented team, and focus on patients offers a tremendous opportunity to address unmet medical need. I look forward to serving as a Board member and supporting Immunome’s important mission.”
Dr. Swain holds an M.D. from the University of Florida and a B.A. in Chemistry from the University of North Carolina at Chapel Hill. Dr. Swain completed a residency in Internal Medicine at Vanderbilt University and a fellowship in Medical Oncology at the National Cancer Institute, National Institutes of Health.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including small molecules, ADCs, RLTs, and immunotherapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.
SOURCE: https://immunome.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.